Cardiome Pharma (CRME) Given a $5.00 Price Target at Canaccord Genuity
Canaccord Genuity set a $5.00 target price on Cardiome Pharma (NASDAQ:CRME) (TSE:COM) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research firms also recently issued reports on CRME. HC Wainwright set a $10.00 target price on shares of Cardiome Pharma and gave the company a buy rating in a report on Wednesday. Mackie upgraded shares of Cardiome Pharma to a buy rating in a research note on Friday, December 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $5.67.
Shares of CRME stock opened at $1.85 on Wednesday. Cardiome Pharma has a twelve month low of $1.29 and a twelve month high of $4.84. The stock has a market cap of $62.00, a P/E ratio of -2.06 and a beta of 0.65. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/cardiome-pharma-crme-given-a-5-00-price-target-at-canaccord-genuity-2/1956221.html.
About Cardiome Pharma
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.